Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

Bone Marrow Transplantation volume 53, pages 366–370 (2018)Cite this article

Subjects

High dose chemotherapy (HDCT) followed by autologous stem cell transplantation in chemorefractory Hodgkin lymphoma (HL) patients resulted in a disappointing long-term progression-free survival (PFS) lower than 30–40% [1,2,3].

Different strategies have been developed: target therapies and risk adapted intensification of salvage treatment. Brentuximab vedotin was associated with an overall response rate >80% [4] and a 5-year overall survival (OS) and PFS of 41 and 22%, respectively [5]. Morschhauser et al. [6] utilized an intensified treatment comprising tandem autologous transplant for high-risk patients according to the SFGM score, showing a 5-year PFS and OS of 46 and 57%.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6:172–9.

    Article  Google Scholar 

  2. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19:1740–4.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–33.

    Article  CAS  PubMed  Google Scholar 

  4. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26:5980–7.

    Article  PubMed  Google Scholar 

  7. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:3918–24.

    Article  CAS  PubMed  Google Scholar 

  8. Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499–504.

    Article  CAS  PubMed  Google Scholar 

  9. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant. 2014;49:190–4.

    Article  CAS  PubMed  Google Scholar 

  10. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:683–8.

    Article  CAS  PubMed  Google Scholar 

  11. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant. 2005;36:443–51.

    Article  CAS  PubMed  Google Scholar 

  12. Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448–55.

    Article  CAS  PubMed  Google Scholar 

  13. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073–2079.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–92.

    Article  CAS  PubMed  Google Scholar 

  15. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.

    Article  PubMed  Google Scholar 

  16. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6.

    Article  CAS  PubMed  Google Scholar 

  17. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–95.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy

    Jacopo Mariotti, Stefania Bramanti, Barbara Sarina, Lucio Morabito, Carmelo Carlo-Stella, Armando Santoro & Luca Castagna

  2. Department of Hematology, Transplantation Program, Marseille, France

    Raynier Devillier, Sabine Furst, Jean El Cheikh, Angela Granata, Catherine Faucher, Samia Harbi, Pierre Jean Weiller & Didier Blaise

  3. Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France

    Christian Chabannon

  4. Aix-Marseille Université, Marseille, France

    Christian Chabannon & Didier Blaise

  5. Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

    Christian Chabannon & Didier Blaise

  6. Intensive Care Unit, Institut Paoli Calmettes, Marseille, France

    Jamel Mokart

  7. Molecular Biology Section, Clinical Investigation Laboratory, Humanitas Cancer Center, Milan, Italy

    Rossana Mineri

  8. Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

    Carmelo Carlo-Stella

  9. Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy

    Armando Santoro

Authors
  1. Jacopo Mariotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefania Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raynier Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean El Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angela Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Catherine Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Samia Harbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lucio Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pierre Jean Weiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Christian Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jamel Mokart
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Rossana Mineri
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Carmelo Carlo-Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Armando Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Luca Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacopo Mariotti.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mariotti, J., Bramanti, S., Devillier, R. et al. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. Bone Marrow Transplant 53, 366–370 (2018). https://doi.org/10.1038/s41409-017-0032-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0032-1

This article is cited by

Search

Advanced search

Quick links